Rofecoxib in migraine

Expert Review of Neurotherapeutics

Volumn 5, Issue 1, 2005, Pages 55-61

  Krymchantowski, Abouch Valenty ^a   Bigal, Marcelo Eduardo ^b  

^a Department of Neurology ^*  (Brazil)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acute treatment; Migraine; Nonsteroidal anti inflammatory drags; Rofecoxib

Indexed keywords

ANTACID AGENT; CYTOCHROME P450; CYTOCHROME P450 3A4; PLACEBO; ROFECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; KAPLAN MEIER METHOD; MIGRAINE; NAUSEA; REVIEW; VOMITING; XEROSTOMIA;

CYCLOOXYGENASE 2 INHIBITORS; EXPERT TESTIMONY; HUMANS; LACTONES; MIGRAINE DISORDERS; SULFONES;

EID: 12344320149     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.1.55     Document Type: Review

References (52)

1. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Neurology 44(Supp 14), S24-S39 (1994).
2. Rasmussen BK. Epidemiology of headache. Cephalalgia 15, 45-68 (1995).
3. Steward WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 16, 231-238 (1996).
4. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin. 15, 1-13 (1997).
5. Headache Classification Subcommittee of The International Headache Society. The International Classification of Headache Disorders. Second Edition. Cephalalgia 24(Suppl. 1), 1-136 (2004).
6. Goadsby PJ, Edvinson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183-187 (1990).
7. Olesen J, Friberg L, Olsen TS et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol. 28, 791-798 (1990).
8. Weiller C, May A, Limmroth V et al. Brain stem activation in spontaneous human migraine attacks. Nature Med. 1, 658-660 (1981).
9. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligoemia and impaired activation of rCBF in classic migraine. Ann. Neurol. 9, 344-352 (1995).
10. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 89, 901-907 (1999).
11. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc. Brain Metab. Rev. 5, 159-177 (1993).
12. Blau JN, Dexter SL. The site of pain origin during migraine attacks. Cephalalgia 1, 143-147 (1981).
13. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2-3), 107-110 (2001).
14. Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 385-389 (2000).
15. Lance JW. Migraine prophylaxis - indication for drug therapy. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Karger, Basel, Switzerland, 250-255 (2000).
16. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Wolff's Headache and Other Head Pain. Seventh Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA, 121-246 (2001).
17. Mathew NT, Silberstein SD. Anticonvulsants in migraine prophylaxis. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Karger, Basel, Switzerland, 288-298 (2000).
18. Dodick DW. Acute and prophylactic management of migraine. Clin. Cornerstone 4, 36-52 (2001).
19. Tfelt-Hansen P, Lipton RB. Prioritizing treatment. In: The Headaches. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Raven Press, NY, USA, 359-362 (1993).
20. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N. Engl. J. Med. 346, 257-270 (2002).
21. Lipton RB, Stewart WF, Cady R et al. 2000 Wolff Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40, 783-791 (2000).
22. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 42(Suppl. 1), 3-9 (2002).
23. 1B/1D receptor agonists in the acute treatment of Migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hanscn P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 411-438 (2000).
24. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 38, 18-22 (1998).
25. Bates D, Ashford E, Dawson R et al. Subcutaneous sumatriptan during the migraine aura. Neurology 44, 1587-1592 (1994).
26. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache 36, 471-475 (1996).
27. Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia 15(Suppl. 15), 21-28 (1995).
28. Visser WH, de Vriend RH, Jaspers NHWM, Ferraria MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46-51 (1996).
29. Tfelt-Hansen P, McEwen J. Nonsteroidal anti-inflammatory drugs in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 391-397 (2000).
30. Limmroth V, Przywara S. Analgesics. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Monogr. Clin. Neurosci. 17, 30-43 (2000).
31. Krymchantowski AV, Silva MT. Intravenous lysine clonixinate for the acute treatment of severe migraine attacks: a double-blind, randomized, placebo-controlled study. Curr. Ther. Res. 64, 505-513 (2003).
32. Ferrari MD, James MH, Bates D et al. Oral sumatriptan: possible benefit of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 14, 330-338 (1994).
33. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22, 309-312 (2002).
34. Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol. Clin. North Am. 25, 363-372 (1996).
35. Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282, 1929-1933 (1999).
36. Silberstein S, Tepper S, Brandes J et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 62(9), 1552-1557 (2004).
37. Lance JW. Headache. Ann. Neurol. 10, 1-10 (1981).
38. Wilkinson M. Treatment of the acute migraine attack - current status. Cephalalgia 3, 61-67 (1983).
39. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurology 4(1), 10 (2004).
40. Vapaatalo H. Tolfenamic acid and migraine - aspects on prostaglandins and leukotrienes. Pharmacol. Toxicol. 75(Suppl. II), 76-80 (1994).
41. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 19, 232-240 (1999).
42. Diener HC, Limmroth V. Analgesics. Curr. Med. Res. Opin. 17(Suppl. 1), S13-S16 (2001).
43. Rasmussen M-JK, Binzer M. Non-steroidal anti-inflammatory drugs in the treatment of migraine. Curr. Med. Res. Opin. 17(Suppl. 1), S26-S29 (2001).
44. Geraud G, Compagnon A, Rossi A, on behalf of the COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur. Neurol. 47, 88-98 (2002).
45. Dib M, Massiou H, Weber M et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 58, 1660-1665 (2002).
46. Matheson AJ, Figgitt DP. Rofecoxib. Drugs 61(6), 833-865 (2001).
47. Vioxx. Vioxx. USPC in PDR (2004).
48. Gottesdiener K, Agrawal N, Porras A et al. Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. Am. J. Ther. 10(4), 252-258 (2003).
49. Silberstein S, Tepper S, Brandes J et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 62, 1552-1557 (2004).
50. MRL MK-0966-162 clinical study reports on file.
51. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8), 633-658 (2002).
52. Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol. 4(1), 4 (2004).